Products

What will AGI do for Bazinaprine?

This classification denotes a monoamine oxidase inhibitor and antidepressant agent with the molecular formula C17H19N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NU8Y4C529J, chemically known as 4-pyridazinecarbonitrile, 3-((2-(4-morpholinyl)ethyl)amino)-6-phenyl- but generally known as bazinaprine, which bears US NIH Compound Identifier 72119. European Medicines Agency schedules Bazinaprine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05672MIG. The term BAZINAPRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). BAZINAPRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bazinaprine under HS 29349990 and SITC 51579. As of Q4 2014, BAZINAPRINE remains the US FDA Preferred Term for this commodity. Bazinaprine bears US NLM identifiers UMLS ID C2346971 and NCI Concept Code C72719. SMILES: O1CCN(CC1)CCNc1nnc(cc1C#N)c1ccccc1.

How AGI delivers it

Four ways AGI delivers for Bazinaprine

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Bazinaprine, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Bazinaprine, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Bazinaprine connects

measured by

  • Compound Puritymodel